ClinicalTrials.gg
RecruitingNCT03933748Updated Apr 14, 2020

Therapeutic Drug Monitoring of Teicoplanin in Children

An observational study in Bacterial Infections, sponsored by Shandong University. Recruiting at 1 site in China. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2020-04-14.

Sponsored by Shandong University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Apr 2019; still recruiting 7 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Bacterial Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. Bacterial Infections · China.

Planned enrollment
10th of 16
500 · median 628
Started
2019
with 4 others
Observational
16 of 32
6 open now
Registered
12th of 32
by date

Among the 32 studies in Bacterial Infections with a site in China, this one is the 10th largest by planned enrollment of the 16 observational ones that give a count, is one of 5 that started in 2019, is one of 16 observational ones, and was the 12th registered.

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

10 of the 32 studies in Bacterial Infections with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Bacterial Infections with a site in China, or all of them as a file.
02

Study summary

In this study, the therapeutic drug monitoring of teicoplanin is carried out among children to obtain the drug concentration, clinical efficacy and safety data of children patients in different gender and age groups. Then we analyze the relationship between blood drug concentration and efficacy and safety, and provide recommendations for the treatment window of teicoplanin in Chinese children.

03

Conditions studied

  • Bacterial Infections

Browse trials for

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children with gram-positive coccus infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Teicoplanin was administered intravenously;
  • Teicoplanin was used for therapeutic purposes;
  • Age:≤18 years;
  • Clinician confirms and plans to diagnose the patient with gram-positive coccus infection;
  • Patients with therapeutic concentration monitoring of teicoplanin.

Exclusion criteria

Exclusion Criteria:

  • Teicoplanin was administered non-intravenously;
  • Teicoplanin was used for prophylactic purposes;
  • Patients without therapeutic concentration monitoring of teicoplanin;
  • Patients who die within 24 hours of the use of teicoplanin;
  • The blood concentrations of the patient was not approved by the quality control center.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Interventions

  • DrugTeicoplanin-PMMA

    Therapeutic drug monitoring of teicoplanin

06

What researchers measure

Primary outcomes

  1. Plasma drug concentration

    To detect the plasma concentrations of teicoplanin at therapeutic drug monitoring (TDM).

    Time frame: Through study completion, an average of 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Nov 2025, 79 months after the start.

Of 74 non-industry observational studies under Bacterial Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 79 months is above that.

Counting every sponsor, half of 81 studies reached it within 22 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2019
First posted
May 1, 2019
StartActual
Apr 1, 2019
Primary completionEst.
Nov 2025
CompletionEst.
Dec 2025
Last update
Apr 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03933748
Collaborators
Qianfoshan Hospital, Shandong Provincial Hospital, Affiliated Hospital of Qinghai University, Jinan children's hospital, Yantai Yuhuangding Hospital, Jinan Central Hospital, Liaocheng People's Hospital, Shandong Tumor Hospital, Weifang People's Hospital, Linyi People's Hospital, Affiliated hospital of jining medical college, Weihai maternal and child health care hospital, The Second Hospital of Shandong University
Responsible party
Wei Zhao (Head of department of clinical pharmacy and pharmacology, Shandong University) — Principal investigator
First posted
May 1, 2019
Start date
Apr 1, 2019
Primary completion
Nov 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 14, 2020

Study contacts

Wei Zhao, Ph.D
Contact
zhao4wei2@hotmail.com
86053188383308

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion